Last updated 18 days ago
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
278 patients around the world
Available in Spain, Brazil, Argentina, United States, Mexico
Bayer
16Research sites
278Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Centro Médico Privado CEMAIC - Córdoba
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Instituto Argentino de Diagnóstico y Tratamiento - IADT
Fundación CENIT para la Investigación en Neurociencias
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Hospital De Base de São José do Rio Preto - CIP São José
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
Hospital de Câncer de Barretos - Fundação PIO XII
StudySOHO-02
SponsorBayer
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06452277
